ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting

    Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data

    Amanda M. Eudy1, Michelle Petri2, Rebecca Fischer-Betz3, Abeer Mokbel4, Cecilia Nalli5, Laura Andreoli5, Angela Tincani6, Yair Molad7, Stephen Balevic8 and Megan E. B. Clowse1, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, 4Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, 5Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 6Spedali Civili and University of Brescia, Brescia, Italy, 7Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 8Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC

    Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
  • Abstract Number: 1298 • 2017 ACR/ARHP Annual Meeting

    Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

    Tayseer Haroun1, Amanda M. Eudy2,3,4,5, Malithi Jayasundara2, W. Benjamin Nowell6,7, Jeffrey R. Curtis8, Charlotte Whitney White9, Rachelle Crow-Hercher9, Seth D. Ginsberg10 and Megan E. B. Clowse4,11, 1Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 2Rheumatology, Duke University Medical Center, Durham, NC, 3Duke University, Durham, NC, 4Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 5Duke University Medical Center, Chapel Hill, NC, 6CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, 7Global Healthy Living Foundation, Upper Nyack, NY, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Arthritis Power, Upper Nyack, NY, 10Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 11Duke University Medical Center, Durham, NC

    Background/Purpose: With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought…
  • Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Nathaniel Harris1, Amanda M. Eudy2 and Megan E. B. Clowse2, 1Duke University School of Medicine, Durham, NC, 2Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC

    Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
  • Abstract Number: 1300 • 2017 ACR/ARHP Annual Meeting

    The Italian Registry of Autoimmune Congenital Heart Block (Lu.Ne Registry): Report of the First Year of Activity

    Micaela Fredi1, Laura Andreoli2, Tiziana Bertero3, Alesandra Bortoluzzi4, Silvia Breda5, Veronica Cappa6, Fulvia Ceccarelli7, Rolando Cimaz8, Salvatore De Vita9, Emma Di Poi10, Franco Franceschini11, Maria Gerosa12, Marcello Govoni4, Ariela Hoxha13, Andrea Lojacono14, Luca Marozio15, Alessandro Mathieu16, Antonina Minniti17, Marina Muscarà18, Melissa Padovan4, Matteo Piga16, Roberta Priori7, Véronique Ramoni19, Amelia Ruffatti13, Marta Tonello13, Sonia Zatti20, Stefano Calza6, Antonio Brucato5 and Angela Tincani2, 1Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 3Ospedale Mauriziano, Torino, Italy, 4UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, 5Struttura Complessa Medicina Interna, ASST Papa Giovanni XXIII, Bergamo, Italy, 6Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, 7UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, 8Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, 9Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, 10Clinica di Reumatologia, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, 11Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 12Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, 13Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, 14Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, 15Ginecologia e Ostetricia 1, Dipartimento di Scienze Chirurgiche, Università di Torino, Torino, Italy, 16Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 17UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Roma, Italy, 18Reumatologia ASST Ospedale Niguarda, Milano, Italy, 19Rheumatology, Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 20U.O. Ginecologia e Ostetricia ASST Spedali Civili, Brescia, Italy

    Background/Purpose: Neonatal Lupus (NL) is a rare syndrome caused by placental transfer of maternal anti-Ro/SSA and anti-La/SSB autoantibodies to the fetus. Cardiac manifestations may comprise…
  • Abstract Number: 1301 • 2017 ACR/ARHP Annual Meeting

    Congenital Heart Defects in Children Born to Mothers with Rheumatic Disease and Anti-Ro and/or Anti-La Antibodies

    Julie Couture1, Linda T Hiraki2, Franklin Silverio1, Deepika Sharma1 and Earl Silverman3, 1Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 2Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Transplacental passage of maternal anti-Ro IgG is thought to be critical in initiating inflammation leading to congenital heart block in neonatal lupus erythematosus (NLE).…
  • Abstract Number: 1302 • 2017 ACR/ARHP Annual Meeting

    Luteinized Unruptured Follicle Syndrome in Young Female with Juvenile Idiopathic Arthritis

    Renato B. B. Tomioka1, Gabriela R.V. Ferreira2, Nadia E Aikawa3, Gustavo A.R. Maciel1, Paulo C. Serafini1, Edmund Baracat1, Lucia M A Campos4, Cláudia Goldenstein-Schainberg3, Rosa M R Pereira3, Eloisa Bonfa5 and Clovis A Silva2, 1Discipline of Gynecology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Juvenile idiopathic arthritis (JIA) may be active during reproductive age, therefore ovarian function and future fertility are relevant issues for its female population. Nonsteroidal…
  • Abstract Number: 1303 • 2017 ACR/ARHP Annual Meeting

    Polycystic Ovarian Syndrome in Rheumatic Disease

    Cuoghi Edens1 and Maria Antonelli2, 1Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, 2Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH

    Background/Purpose:  Polycystic ovarian syndrome (PCOS) is a common entity in the general population associated with polycystic ovaries, oligomenorrhea, difficulty conceiving, hormone abnormalities, metabolic comorbidities, and…
  • Abstract Number: 1304 • 2017 ACR/ARHP Annual Meeting

    Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with SLE in Saginaw Valley, a High Risk Population

    J. Patricia Dhar1,2, Lynnette Essenmacher3, Renee Dhar4, Neli Ragina5 and Robert Sokol6, 1Internal Medicine, Wayne State University School of Medicine, Detroit, MI, 2Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, 3Wayne State University School of Medicine, Detroit, MI, 4CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, 5Foundational Sciences, Central Michigan University College of Medicine, Mount Pleasant, MI, 6Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI

    Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely due to infection with high risk (HR) HPV and thus should be considered…
  • Abstract Number: 1305 • 2017 ACR/ARHP Annual Meeting

    Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen

    Arielle Mendel1, Sasha Bernatsky2, Yvan St.Pierre3, Christian Pineau4 and Evelyne Vinet5, 1Rheumatology, McGill University, Montreal, QC, Canada, 2Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4Rheumatology, McGill University Health Center, Montreal, QC, Canada, 5Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Estrogen-containing contraceptives may be contraindicated in specific medical conditions due to an increased risk of cardiovascular and thromboembolic events. Women with SLE are at…
  • Abstract Number: 1306 • 2017 ACR/ARHP Annual Meeting

    Predictors of Contraceptive Use Among Reproductive-Age Women with Rheumatic Diseases

    Mehret Birru Talabi1 and Sonya Borrero2, 1Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Contraception helps reproductive-age women with rheumatic diseases to avoid or plan pregnancies so that disease quiescence on safe medications may first be achieved. However,…
  • Abstract Number: 1307 • 2017 ACR/ARHP Annual Meeting

    Contraceptive Use in Patients with Rheumatologic Disease on Teratogenic Medications: Rate of Use and Related Factors

    Shanley O'Brien1 and Megan Krause2, 1Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, 2Division of Allergy, Clinical Immunology, and Rheumatology, Kansas University Medical Center, Kansas City, KS

    Background/Purpose: Rheumatologic diseases can affect females of reproductive age. Medications utilized for treatment of these diseases can be associated with harmful consequences in pregnancy. Unfortunately,…
  • Abstract Number: 1308 • 2017 ACR/ARHP Annual Meeting

    Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception

    Malithi Jayasundara1, Amanda M. Eudy2, Tayseer Haroun3, W. Benjamin Nowell4, Jeffrey R. Curtis5, Rachelle Crow-Hercher6, Charlotte Whitney White6, Seth D. Ginsberg7 and Megan E. B. Clowse8, 1Rheumatology, Duke University, Durham, NC, 2Duke University, Durham, NC, 3Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 4Global Healthy Living Foundation, Upper Nyack, NY, 5University of Alabama at Birmingham, Birmingham, AL, 6Arthritis Power, Upper Nyack, NY, 7Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 8Duke University Medical Center, Durham, NC

    Background/Purpose: Women with arthritis wonder whether they will be able to have the children they desire. They also worry that oral contraceptives may worsen their…
  • Abstract Number: 1309 • 2017 ACR/ARHP Annual Meeting

    Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

    Megan E. B. Clowse1, Angela E. Scheuerle2, Christina D Chambers3, Anita Afzali4, Alexa Kimball5, John J. Cush6, Maureen Cooney7, Laura Shaughnessy7, Mark Vanderkelen8 and Frauke Förger9, 1Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 2UT Southwestern Medical Center, Dallas, TX, 3UC San Diego School of Medicine, San Diego, CA, 4University of Washington Harborview Medical Center, Seattle, WA, 5Beth Israel Deaconess Medical Center, Boston, MA, 6Baylor Scott & White Research Institute, Dallas, TX, 7UCB Pharma, Raleigh, NC, 8UCB Pharma, Braine-l’Alleud, Belgium, 9Inselspital, University of Bern, Bern, Switzerland

    Background/Purpose: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently,…
  • Abstract Number: 1310 • 2017 ACR/ARHP Annual Meeting

    Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy

    Geneviève Genest1, Karen Spitzer2 and Carl Laskin3, 1Allergy-Immunology, McGill University and McGill University Health Center, Montreal, QC, Canada, 2Trio Fertility, Toronto, ON, Canada, 3Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during pregnancy but are frequently withheld in the second or third trimester to minimize transplacental transfer…
  • Abstract Number: 1311 • 2017 ACR/ARHP Annual Meeting

    Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)

    Yan Zhao1, lingxun shen2, zongwen shuai3, Hengli Zhao4, Weinan Lai5, Xiaoling Lai6, Shaoying Zhang7, Xuequn Wang8, Shaoxian Hu9, Wenli Chen10, Wei Ji11, Hua Wei12, Qi Zhang13, Lixia Pang14, huaxiang Liu15, Qiang Shu15, Jun-li Zhang16, Yating Zhou17, Qiong Jiang18, Huaxiang Wu19, Jing Xue19, Ganping Bai20, Li Zhang21 and Fei Xiao21, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Wuhan Union Hospital, wuhan, China, 3The First Affiliated Hospital of Anhui University, Hefei, China, 4Yantai Hospital of Traditional medicine University, Yantai, China, 5Nanfang Hospital, Guangzhou, China, 6Guangxi Hospital of Traditional Chinese Medicine, Nanning, China, 7Yiling Hospital, Yiling, China, 8The First Affiliated Hospital of Xinyang, Xinyang, China, 9Tongji hospital, wuhan, China, 10Wuhan Central Hospital, wuhan, China, 11Jiangsu Province Hospital of TCM, Nanjing, China, 12Subei People's Hospital, Yangzhou, China, 13Dongying central hospital, Dongying, China, 14Dongying Hospital, Dongying, China, 15Qilu hospital of Shandong University, Jinan, China, 16Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, 17Xian No5 Hospital, Shandong, China, 18Taizhou Hospital, Taizhou, China, 19The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 20Chongqing Southwest Hospital, Chongqing, China, 21Gothic Internet Technology Corporation, Shanghai, China

    Background/Purpose: LEF is a first line DMARD. Due to the teratogenic effects in offspring of rats in preclinical study, the patients who plan to get…
  • « Previous Page
  • 1
  • …
  • 1290
  • 1291
  • 1292
  • 1293
  • 1294
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology